FEATURES OF THE FORMATION OF THE IMMUNE RESPONSE AFTER VACCINATION AGAINST COVID-19

Authors

  • H. L. Kyseliova DILA Medical Laboratory
  • I. A. Anastasiy O. Bogomolets National Medical University
  • O. B. Tonkovyd DILA Medical Laboratory
  • V. M. Isaiev DILA Medical Laboratory
  • K. V. Voronova DILA Medical Laboratory
  • I. I. Shevel DILA Medical Laboratory
  • I. V. Sidorova DILA Medical Laboratory
  • S. V. Karpechenko DILA Medical Laboratory
  • A. A. Panchenko DILA Medical Laboratory

DOI:

https://doi.org/10.11603/1681-2727.2022.4.13697

Keywords:

immune response

Abstract

The aim of the study is to evaluate the immune response of vaccinated against COVID-19 among the employees of LLC ML “DILA”, to study the serum levels of such monitoring indicators as immunoglobulins M and G in the case of using different vaccines.

Materials and methods. In this study serum levels of M and G immunoglobulins to various coronavirus target proteins (S spike protein, N protein) were measured longitudinally in 603 employees vaccinated against COVID-19 with CoronaVac, Pfizer-BioNTech, AstraZeneca, Moderna. Immunochemiluminescent analyzer was used to determine serum levels of M and G immunoglobulins.

Results. An immune response was found among 99.2 % vaccinated compared to 73.3 % among recovered from COVID-19. All vaccinated individuals produce protective antibodies, regardless of the history of COVID-19 prior to vaccination. These antibodies were present for at least 4 months after vaccination, with fluctuations in their number depending on the type of vaccine received. The Pfizer-BioNTech RNA vaccine provided the most stable antibody levels.

Conclusions. The duration of the immune response (according to the results of the determination of antibodies after vaccination) indicates the effectiveness of vaccination and the advisability of uses a booster doses of the vaccine.

Author Biographies

H. L. Kyseliova, DILA Medical Laboratory

ML DILA, sector of Infectology

I. A. Anastasiy, O. Bogomolets National Medical University

ML DILA, medical monitoring specialist

 

O. B. Tonkovyd, DILA Medical Laboratory

PhD, Associate Professor of the Department of Infectious Diseases of O. Bogomolets National Medical University

V. M. Isaiev, DILA Medical Laboratory

ML DILA, sector of Infectology

K. V. Voronova, DILA Medical Laboratory

ML DILA, sector of Infectology

I. I. Shevel, DILA Medical Laboratory

ML DILA, Head of the sanitary-epidemiological regime group

I. V. Sidorova, DILA Medical Laboratory

ML DILA, Medical Director

S. V. Karpechenko, DILA Medical Laboratory

ML DILA, Manager of the personnel motivation and accounting group

A. A. Panchenko, DILA Medical Laboratory

ML DILA, HR manager

References

Townsend, J. P., Hassler, H.B., Wang, Z., Miura, S., Singh, J., Kumar, S. et al. (2021) The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe. 2(12),666-675. https://doi.org/10.1016/S2666-5247(21)00219-6 DOI: https://doi.org/10.1016/S2666-5247(21)00219-6

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E. et al. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (New York, N.Y.), 371(6529), eabf4063. https://doi.org/10.1126/science.abf4063 DOI: https://doi.org/10.1126/science.abf4063

Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo et al. (2021). Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature communications, 12(1), 1018. https://doi.org/10.1038/s41467-021-21336-8 DOI: https://doi.org/10.1038/s41467-021-21336-8

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A. et al. (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 584(7821), 437–442. https://doi.org/10.1038/s41586-020-2456-9 DOI: https://doi.org/10.1038/s41586-020-2456-9

Qu, J., Wu, C., Li, X., Zhang, G., Jiang, Z., Li, X. et al. (2020). Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 71(16), 2255–2258. https://doi.org/10.1093/cid/ciaa489 DOI: https://doi.org/10.1093/cid/ciaa489

Kyseliova, H., Anastasii, I., Tonkovyd, O., Isaiev, V., Sidorova, I., & Voronova, K. (2021). Features of the immune response formation to SARS-CoV-2 in patients who have recovered from COVID-19. ACTUAL INFECTOLOGY, 9(3), 12–19. https://doi.org/10.22141/2312-413X.9.3.2021.236225 DOI: https://doi.org/10.22141/2312-413X.9.3.2021.236225

Abu-Raddad, L. J., Chemaitelly, H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A. et al. (2021). SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95 % efficacy. EClinicalMedicine, 35, 100861. https://doi.org/10.1016/j.eclinm.2021.100861 DOI: https://doi.org/10.1016/j.eclinm.2021.100861

Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose. Retrieved from https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm

COVID-19 after Vaccination: Possible Breakthrough Infection https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html

Pilishvili, T., Fleming-Dutra, K. E., Farrar, J.L., Gierke, R., Mohr, N. M., Talan, D. A. et al. (2021) Vaccine Effectiveness Among Healthcare Personnel Study Team. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep. 70(20),753-758. https://doi.org/ 10.15585/mmwr.mm7020e2. DOI: https://doi.org/10.15585/mmwr.mm7020e2

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577 DOI: https://doi.org/10.1056/NEJMoa2034577

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R. et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England Journal of Medicine, 384(5), 403–416. https://doi.org/10.1056/NEJMoa2035389 DOI: https://doi.org/10.1056/NEJMoa2035389

Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-Garcia, J., O’Horo et al. (2021). Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. MedRxiv: the Preprint Server for Health Sciences, 2021.08.06.21261707. https://doi.org/10.1101/2021.08.06.21261707 DOI: https://doi.org/10.1101/2021.08.06.21261707

Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A. et al. (2021). BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature Medicine, 27 (12), 2136–2143. https://doi.org/10.1038/s41591-021-01583-4 DOI: https://doi.org/10.1038/s41591-021-01583-4

Tada, T., Zhou, H., Samanovic, M. I., Dcosta, B. M., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021). Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants. BioRxiv: The Preprint Server for Biology, 2021.07.19.452771. https://doi.org/10.1101/2021.07.19.452771 DOI: https://doi.org/10.1101/2021.07.19.452771

WHO. The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what you need to know. Retrieved from https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know

WHO. The Sinovac-CoronaVac COVID-19 vaccine: What you need to know. Retrieved from https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know

Downloads

Published

2023-04-14

How to Cite

Kyseliova, H. L., Anastasiy, I. A., Tonkovyd, O. B., Isaiev, V. M., Voronova, K. V., Shevel, I. I., … Panchenko, A. A. (2023). FEATURES OF THE FORMATION OF THE IMMUNE RESPONSE AFTER VACCINATION AGAINST COVID-19. Infectious Diseases – Infektsiyni Khvoroby, (4), 10–19. https://doi.org/10.11603/1681-2727.2022.4.13697

Issue

No. 4 (2022)

Section

Original investigations

License

Copyright (c) 2023 Infectious diseases

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration

Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes

 Лицензия Creative Commons

This journal is available through Creative Commons (CC) License  BY-NC "Attribution-NonCommercial" 4.0